Your browser doesn't support javascript.
loading
Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.
Grunst, Michael W; Gil, Hwi Min; Grandea, Andres G; Snow, Brian J; Andrabi, Raiees; Nedellec, Rebecca; Burton, Iszac; Clark, Natasha M; Janaka, Sanath Kumar; Keles, Nida K; Moriarty, Ryan V; Weiler, Andrea M; Capuano, Saverio; Fennessey, Christine M; Friedrich, Thomas C; O'Connor, Shelby L; O'Connor, David H; Broman, Aimee T; Keele, Brandon F; Lifson, Jeffrey D; Hangartner, Lars; Burton, Dennis R; Evans, David T.
Affiliation
  • Grunst MW; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Gil HM; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Grandea AG; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Snow BJ; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Andrabi R; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Nedellec R; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Burton I; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
  • Clark NM; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Janaka SK; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
  • Keles NK; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Moriarty RV; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
  • Weiler AM; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Capuano S; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Fennessey CM; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Friedrich TC; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • O'Connor SL; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • O'Connor DH; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Broman AT; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Keele BF; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Lifson JD; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Hangartner L; Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Burton DR; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Evans DT; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
PLoS Pathog ; 20(1): e1011819, 2024 Jan.
Article in En | MEDLINE | ID: mdl-38252675
ABSTRACT
Fc-mediated antibody effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), can contribute to the containment HIV-1 replication but whether such activities are sufficient for protection is unclear. We previously identified an antibody to the variable 2 (V2) apex of the HIV-1 Env trimer (PGT145) that potently directs the lysis of SIV-infected cells by NK cells but poorly neutralizes SIV infectivity. To determine if ADCC is sufficient for protection, separate groups of six rhesus macaques were treated with PGT145 or a control antibody (DEN3) by intravenous infusion followed five days later by intrarectal challenge with SIVmac239. Despite high concentrations of PGT145 and potent ADCC activity in plasma on the day of challenge, all animals became infected and viral loads did not differ between the PGT145- and DEN3-treated animals. To determine if PGT145 can protect against a neutralization-sensitive virus, two additional groups of six macaques were treated with PGT145 and DEN3 and challenged with an SIVmac239 variant with a single amino acid change in Env (K180S) that increases PGT145 binding and renders the virus susceptible to neutralization by this antibody. Although there was no difference in virus acquisition, peak and chronic phase viral loads were significantly lower and time to peak viremia was significantly delayed in the PGT145-treated animals compared to the DEN3-treated control animals. Env changes were also selected in the PGT145-treated animals that confer resistance to both neutralization and ADCC. These results show that ADCC is not sufficient for protection by this V2-specific antibody. However, protection may be achieved by increasing the affinity of antibody binding to Env above the threshold required for neutralization.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Simian Acquired Immunodeficiency Syndrome / Simian Immunodeficiency Virus Type of study: Prognostic_studies Limits: Animals Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Simian Acquired Immunodeficiency Syndrome / Simian Immunodeficiency Virus Type of study: Prognostic_studies Limits: Animals Language: En Year: 2024 Type: Article